Safinamide mesylate is under clinical development by Zambon Co and currently in Phase II for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration). According to GlobalData, Phase II drugs for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Safinamide mesylate LoA Report. Buy the report here.
Aurobindo's Generic Safinamide Mesylate Receives Approval in the U.S.
RK Pharma Receives Generic Safinamide Mesylate Tentative Approval in the U.S.A
Optimus' Generic Safinamide Mesylate Receives Approval in the U.S.
Optimus' Generic Safinamide Receives Approval in the U.S.
MILAN--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the half year ended June 30, 2022 and provided an update on its R&D and business activities.
Newron and Zambon sign agreement for potentially pivotal study with safinamide in Parkinson’s disease patient
MILAN, Italy--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced an agreement regarding a potentially pivotal study to evaluate the efficacy of safinamide in Parkinson’s disease patients with levodopa induced dyskinesia (PD LID). Positive results from the study could result in a label extension for safinamide, subject to regulatory approval.
MILAN, Italy--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced an agreement regarding a potentially pivotal study to evaluate the efficacy of safinamide in Parkinson’s disease patients with levodopa induced dyskinesia (PD LID). Positive results from the study could result in a label extension for safinamide, subject to regulatory approval.